KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Chemical Optimization of Cerebral Embolectomy 2 (CHOICE 2) trial: study protocol.

Arturo Renú, Patricia de la Riva, Raquel Delgado-Mederos, Laura Dorado, Maria Dolores Fernandez-Couto, Maria Herrera-Isasi, Nicolás López Hernández, Ana Morales, Lluis Morales-Caba, Pol Camps-Renom, Alba Singla, Mikel Terceño, Pedro Vega, Sergio Amaro, Jordi Blasco, Carlos Laredo, Enrique C Leira, Laura Oleaga, Joaquin Serena, Xabier Urra, Mariano Werner, Francisco Hernández Fernández, Joan Valls, Juan Francisco Arenillas Lara, Maria Del Mar Freijo, Natalia Pérez de la Ossa, Luis San Roman, Ferran Torres, Mar Castellanos, Antonio Davalos, Angel Chamorro, CHOICE 2 Investigators

Stroke Vasc Neurol svn-2025-004279

PMID41339082
PMCID-
DOI10.1136/svn-2025-004279
发表日期2025-12-03
摘要

摘要

RATIONALE: The potential value of rescue intra-arterial thrombolysis in patients with large vessel occlusion (LVO) stroke treated with mechanical thrombectomy (MT) remains to be validated in randomised trials. AIM: The Chemical Optimization of Cerebral Embolectomy 2 (CHOICE 2) trial is designed to confirm whether adjunctive intra-arterial alteplase, administered after successful MT, improves clinical outcomes in patients with LVO stroke. SAMPLE SIZE ESTIMATES: A total of 440 patients (220 per group) randomised in a 1:1 ratio to receive intra-arterial thrombolysis or not intra-arterial thrombolysis provides 80% statistical power to detect a 14% absolute benefit in the primary endpoint (the proportion of patients achieving modified Rankin Scale (mRS) 0-1 at 90 days), assuming a rate of 40% in the control group, a 5% two-sided type I error. The sample size also provides >95% power for detecting an 18% absolute benefit in secondary imaging endpoints, assuming a 58% rate in the control group. METHODS AND DESIGN: Multicentre, randomised, open, blinded end-point assessment phase III trial. Eligible patients are adults (≥18 years) with symptomatic LVO who undergo MT with successful or complete reperfusion at end of the procedure. Patients in the intervention group will receive a 15 min intra-arterial infusion of alteplase (1.0 mg/mL, maximum dose 20 mg). STUDY OUTCOMES: The primary outcome is the proportion of patients achieving excellent functional outcome (mRS 0-1) at 90 days. Key secondary outcomes are the presence of hypoperfusion on brain CT perfusion at 36±24 hours post randomisation, infarct expansion, Barthel Index and quality of life. Mortality and symptomatic intracerebral haemorrhage will also be evaluated. DISCUSSION: This trial will provide evidence whether rescue intra-arterial thrombolysis improves clinical outcome in patients with LVO stroke who achieve successful or complete angiographic reperfusion following MT.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。